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Introduction
In patients with mechanical heart valves, use of direct oral anticoagulants (DOACs) is currently
contraindicated, and their use in patients with bioprosthetic heart valves is off-label.1,2 We sought to
determine the current state of use of DOACs in patients with surgical prosthetic heart valves in the
US and evaluate differences in preoperative and postoperative profiles among patients discharged
while receiving DOACs vs warfarin.
Methods
This retrospective cohort study was conducted using data extracted from the Society of Thoracic
Surgeons Adult Cardiac Surgery Database risk calculator, version 2.81.3 Patients who underwent
surgical aortic valve replacement or mitral valve replacement with either mechanical heart valves or
bioprosthetic heart valves between July 2014 and June 2017 were included. Data were analyzed from
May 1 to September 30, 2020. Patients who were not alive at the time of discharge were excluded.
Descriptive analyses were performed to summarize variables. The Cleveland Clinic institutional
review board determined this study to be exempt from review owing to use of deidentified data, with
institutional-determined waiver of informal consent (oral or written). This study followed the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline
for cohort studies. Statistical analysis was performed using Python, version 3.6.7 (Python Software
Foundation) and Microsoft Excel (Microsoft Corp). Statistical significance was set at 2-tailed P < .05.
Results
The study population comprised 177 915 patients; 62% were male and 38% were female. The mean
(SD) age of the study population was 62.2 (10.8) years. The use of DOACs was observed among
78.6% (858 0f 1092) hospitals and 59.6% (1627 of 2731) physicians captured in the STS database. In
patients undergoing aortic valve replacement with mechanical heart valves (n = 18 142), the overall
use of DOACs at discharge over the study period was 1.1% (193 of 18 142; 129 patients received factor
Xa inhibitors, and 69 patients received thrombin inhibitors): 1.25% in 2014, 0.99% in 2015, 1.09%
in 2016, and 1.17% in 2017 for aortic valve replacement (P = .84 for trend) (Figure). In patients
undergoing mitral valve replacement with mechanical heart valves (n = 13 942), the overall use of
DOACs at discharge over the study period was 1.04% (139 of 13 942; 94 patients received factor Xa
inhibitors, and 46 patients received thrombin inhibitors): 1.25% in 2014, 0.91% in 2015, 1.16% in
2016, and 0.93% in 2017 (P = .45 for trend). In patients undergoing aortic valve replacement with
bioprosthetic heart valves (n = 116 203), the overall use of DOACs over the study period was 4.66%
(5625 of 116 203; 4622 patients received factor Xa inhibitors, and 680 patients received thrombin
inhibitors), and the use increased over the study period: 3.30% in 2014, 3.80% in 2015, 5.14% in
2016, and 6.64% in 2017 (P = .02 for trend). In patients undergoing mitral valve replacement
(n = 39 243) with bioprosthetic heart valves, the overall use of DOACs over the study period was
5.89% (2180 of 39 243; 1906 patients received factor Xa inhibitors, and 289 patients received
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thrombin inhibitors), and the use increased over the study period: 3.94% in 2014, 4.97% in 2015,
5.66% in 2016, and 7.72% in 2017 for mitral valve replacement (P = .03 for trend).
In patients receiving aortic valve replacement or mitral valve replacement with mechanical
heart valves, 88 patients were discharged receiving exclusively DOAC (no warfarin), and 26 474
receiving exclusively warfarin (no DOAC). Of these, patients discharged receiving DOAC were older
(mean [SD] age, 60.8 [12.5] years) compared with those discharged receiving warfarin (mean [SD]
age, 53 [11.8] years) (P < .001), and there was a greater prevalence of preoperative hypertension
(83.0% [73 of 88] vs 68.0% [17 974 of 26 398]; P = .003), dyslipidemia (69.3% [61 of 88] vs 57.0%
[14 926 of 26 351]; P = .02), peripheral arterial disease (18.2% [16 of 88] vs 6.6% [1747 of 26 331];
P < .001), heparin-induced thrombocytopenia antibody (14.0% [2 of 14] vs 1.9% [86 of 4490];
P < .001), and lower mean (SD) international normalized ratio (1.07 [0.15] vs 1.13 [0.4]; P < .001)
(Table). Preoperative use of factor Xa inhibitors was significantly higher for patients discharged
receiving DOAC than for those discharged receiving warfarin (3.8% [3 of 80] vs 0.3% [73 of 24 721];
P < .001). Postoperative (before discharge) events were also higher in patients discharged receiving
DOACs than for those discharged receiving warfarin, such as atrial fibrillation or flutter (43.0% [38 of
88] vs 22.0% [5834 of 26 474]; P < .001), reoperation for bleeding (9.1% [8 of 88] vs 3.0% [783 of
26 474]; P = .001), venous thromboembolism (3.4% [3 of 88] vs 0.5% [138 of 26 474]; P = .001),
pulmonary thromboembolism (1.1% [1 of 88] vs 0.04% [11 of 26 474]; P < .001), and deep vein
thrombosis (3.4% [3 of 88] vs 0.4% [112 of 26 474]; P < .001).
In patients receiving aortic valve replacement or mitral valve replacement with bioprosthetic
heart valves, 6740 patients were discharged receiving exclusively DOAC (no warfarin), and 48 107
receiving exclusively warfarin (no DOAC). There was a greater prevalence of preoperative
arrhythmias (54.8% [3683 of 6725] vs 42.0% [20 109 of 47 947]; P < .001), and a lesser prevalence
of dialysis (2.0% [132 of 6726] vs 3.2% [1555 of 48 039]; P < .001) and heparin-induced
thrombocytopenia antibody (3.3% [34 of 1022] vs 2.3% [192 of 8324]; P < .001) in patients
discharged receiving DOAC. Preoperative use of factor Xa inhibitors (2.6% [165 of 6300] vs 0.5%
[220 of 44 853]; P < .001) and thrombin inhibitors (0.5% [33 of 6322] vs 0.2% [100 of 44 969];
P < .001) was higher in patients discharged receiving DOAC than for those discharged receiving
warfarin. Patients discharged receiving DOAC had lesser postoperative (before discharge) events like
kidney failure (2.2% [150 of 6740] vs 2.8% [1368 of 48 107]; P < .001) and reoperation for bleeding
(2.6% [176 of 6740] vs 3.4% [1647 of 48 107]; P < .001), but occurrence of postoperative events like
atrial fibrillation or flutter (47.7% [3213 of 6740] vs 40.0% [19 239 of 48 107]; P < .001), venous
thromboembolism (2.5% [168 of 6740] vs 1.8% [870 of 48 107]; P < .001), and DVT was higher in
patients discharged receiving DOACs (2.1% [143 of 6740] vs 1.5% [717 of 48 107]; P < .001).


























There were 2365 (1.33%) patients who received both
aortic and mitral mechanical valves, and 7025 (3.94%)
patients who received both aortic and mitral
bioprosthetic valves.
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Table. Differences in Preoperative and Postoperative Profiles Among Patients With Prosthetic Heart Valves Discharged Receiving DOACs vs Warfarin
Characteristic
Mechanical Bioprosthetic
DOAC (n = 88)a Warfarin (n = 26 474)
P value
DOAC (n = 6740)b Warfarin (n = 48 107)
P valueTotal No.a No. (%) Total No.c No. (%) Total No.c No. (%) Total No.c No. (%)
Demographic
Age, mean (SD) y 88 60.8 (12.5) 26 474 53 (11.8) <.001 6740 66.3 (7.8) 48 107 65.0 (9.0) <.001
Female 88 40 (45) 26 474 11 634 (44) .62 6740 2384 (35) 48 107 19 115 (40) <.001
Male 88 48 (55) 26 474 14 827 (56) .65 6740 4353 (65) 48 107 28 980 (60) <.001
Weight, mean (SD), kg 88 88.2 (24.3) 26 474 88.8 (23.8) .82 6740 99.6 (22.5) 48 107 88.4 (21.6) <.001
Height, mean (SD), cm 88 172 (11) 26 474 171 (11.3) .45 6740 172 (10.6) 48 107 171 (10.8) <.001
Preoperative
Diabetes 88 26 (29.5) 26 412 6369 (24) .20 6728 2405 (35.7) 48 025 15 992 (33) <.001
Hypertension 88 73 (83) 26 398 17 974 (68) .003 6731 5798 (86.1) 48 035 38 728 (81) <.001
Dyslipidemia 88 61 (69.3) 26 351 14 926 (57.0) .02 6717 5135 (76.4) 47 953 34 805 (73) <.001
Dialysis 88 3 (3.4) 26 418 1210 (4.6) .46 6726 132 (2.0) 48 039 1555 (3.2) <.001
Arrhythmia 88 41 (47) 26 368 8023 (30) <.001 6725 3683 (54.8) 47 947 20 109 (42.0) <.001
Arrhythmia (atrial fibrillation) 40 36 (90) 7921 6686 (84) .32 3658 3298 (90) 19 959 17 678 (89) <.001
Cerebrovascular disease 88 18 (20.5) 26 251 4011 (15.3) .15 6712 1492 (22.2) 47 829 9422 (19.7) <.001
Peripheral arterial disease 88 16 (18.2) 26 331 1747 (6.6) <.001 6714 770 (11.5) 47 906 4941 (10.3) <.001
Endocarditis 88 6 (6.8) 26 436 3585 (13.6) .06 6734 511 (7.6) 48 055 4539 (9.4) <.001
Prior myocardial infarction 85 15 (17.6) 26 301 3294 (12.5) .13 6701 1286 (19.2) 47 823 8770 (18.3) <.001
Thoracic aortic disease 88 3 (3.4) 26 270 1791 (6.8) .17 6687 414 (6.2) 47 862 2645 (5.5) <.001
Liver disease 88 6 (6.8) 26 234 1318 (5.0) .35 6674 334 (5.0) 47 766 2312 (4.8) <.001
Hematocrit, mean (SD) 88 37.6 (6.5) 26 474 38.8 (5.9) .08 6740 39.2 (5.7) 48 107 38.7 (5.8) <.001
Platelets, mean (SD) 88 224 598
(75 325)
26 474 225 494
(76 173)
.91 6740 211 596
(70 625)





88 1.07 (0.15) 26 474 1.13 (0.4) <.001 6740 1.11 (0.21) 48 107 1.15 (0.37) <.001
Heparin-induce
thrombocytopenia antibody
14 2 (14.0) 4490 86 (1.9) <.001 1022 34 (3.3) 8324 192 (2.3) <.001
Preoperative medication
Aspirin 87 40 (46) 26 308 11 323 (43) .49 6691 3556 (53.1) 47 834 24 679 (52) <.001
Warfarin 81 0 (0) 24 782 369 (1.5) .22 6323 25 (0.4) 44 934 743 (1.7) <.001
Adenosine diphosphate inhibitors
(within 5 d)
88 2 (2.3) 26 375 386 (1.5) .41 6707 150 (2.2) 47 955 1018 (2.1) <.001
Glycoprotein IIb/IIIa inhibitor 88 0 (0) 26 389 44 (0.2) .51 6711 21 (0.3) 47 992 94 (0.2) <.001
Factor Xa inhibitors 80 3 (3.8) 24 721 73 (0.3) <.001 6300 165 (2.6) 44 853 220 (0.5) <.001
Antiplatelets (within 5 d) 81 2 (2.5) 24 794 446 (1.8) .50 6323 91 (1.4) 44 974 975 (2.2) <.001
Thrombolytics 88 0 (0) 26 379 37 (0.14) .52 6714 10 (0.15) 47 993 42 (0.1) <.001
Thrombin inhibitors 81 0 (0) 24 784 43 (0.17) .52 6322 33 (0.5) 44 969 100 (0.2) <.001
Postoperative event
Kidney failure 88 3 (3.4) 26 474 648 (2.4) .43 6740 150 (2.2) 48 107 1368 (2.8) <.001
Atrial fibrillation or flutter 88 38 (43.0) 26 474 5834 (22.0) <.001 6740 3213 (47.7) 48 107 19 239 (40.0) <.001
Anticoagulant events 88 2 (2.3) 26 474 275 (1.0) .21 6740 120 (1.8) 48 107 824 (1.7) <.001
Reoperation for bleeding 88 8 (9.1) 26 474 783 (3.0) <.001 6740 176 (2.6) 48 107 1647 (3.4) <.001
Stroke 88 3 (3.4) 26 474 330 (1.2) .06 6740 135 (2.0) 48 107 819 (1.7) <.001
Tamponade 88 0 (0) 26 474 59 (0.2) .49 6740 8 (0.11) 48 107 60 (0.1) <.001
Transient ischemic attack 88 1 (1.1) 26 474 58 (0.2) .06 6740 25 (0.37) 48 107 159 (0.3) <.001
Venous thromboembolism 88 3 (3.4) 26 474 138 (0.5) .001 6740 168 (2.5) 48 107 870 (1.8) <.001
Reoperation for valve dysfunction 88 0 (0) 26 474 48 (0.2) .50 6740 5 (0.07) 48 107 69 (0.1) <.001
New dialysis requirement 88 2 (2.3) 26 474 403 (1.5) .43 6740 89 (1.3) 48 107 888 (1.8) <.001
Pulmonary thromboembolism 88 1 (1.1) 26 474 11 (0.04) <.001 6740 25 (0.37) 48 107 124 (0.3) <.001
Deep vein thrombosis 88 3 (3.4) 26 474 112 (0.4) <.001 6740 143 (2.1) 48 107 717 (1.5) <.001
Abbreviation: DOAC, direct oral anticoagulants.
a A total of 67 patients received factor Xa inhibitor and 22 received thrombin-inhibitor.
b A total of 5993 patients received factor Xa inhibitor and 769 received thrombin-inhibitor.
c Number of patients with data available.
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Discussion
The main limitation of this study is the lack of follow-up data to compare outcomes of DOACs vs
warfarin in patients with prosthetic valves. Despite this limitation, our study suggests a prevailing
off-label use of DOACs in patients with prosthetic heart valves without satisfactory safety data. Until
the completion of randomized clinical trials that provide sufficient evidence for DOAC use, physicians
may wish to exercise caution with regard to DOAC prescription for patients with prosthetic
heart valves.
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